Skip to main content
Clinical Trials/JPRN-jRCT1060200019
JPRN-jRCT1060200019
Recruiting
未知

Clinical and molecular background associated with obinituzumab response in follicular lymphoma

Maeda Yoshinobu0 sites200 target enrollmentOctober 9, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Maeda Yoshinobu
Enrollment
200
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 9, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Maeda Yoshinobu

Eligibility Criteria

Inclusion Criteria

  • 1\) Histologically proven CD20 positive follicular lymphoma (Grade 1, 2, 3A).
  • 2\) Age 70\-year\-old or more.
  • 3\) Treated by GB therapy as an initial therapy.
  • 4\) Written informed consent

Exclusion Criteria

  • Patients who refuse to participate in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials